CURRICULUM VITAE

Hamid Asadzadeh Aghdaei, M.D.

PERSONAL INFORMATION

Date of Birth: August 5, 1970
Place of Birth: Mashhad, Iran
Nationality: Iranian
Professional address and telephone: Research Institute for Gastroenterology and Liver Disease, Taleghani Hospital, Evin, Tehran, Iran. +982122432539
E-mail address: hamid.asadzadeh@sbmu.ac.ir

EDUCATION/POST GRADUATE TRAINING

Medical School: 1988-1996 Medical school, 7 years, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
Residency: 1999-2003 Internal Medicine specialty program, 4 years, at Shahid Beheshti Medical University. Tehran, Iran**.** Board certified
Fellowship: 2009-2011 Gastroenterology & hepatology Fellowship program at Shahid Beheshti Medical University. Tehran, Iran. Board certified
Other: 2013-2014 Master of Science in research

PROFESSIONAL PROCEDURES

- Diagnostic & Therapeutic Endoscopy and Colonoscopy.
- Balloon Enteroscopy.
- Therapeutic ERCP.
- Cholangioscopy.
- Therapeutic Endosonography.
- EMR & ESD
- POEM

LANGUAGE SKILLS

- English: Passing Academic IELTS exam, 2005. Overall score: 6.5
- Persian: (Native language)

Google scholar H index: 15

ACHIEVEMENTS

Books:

- Instructional Package for Diagnosis and Treatment of Gallstone. Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical sciences.
- Instructional Package for Diagnostic Endosonography Techniques. Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical sciences.

Published Articles:

1. Frequency of post-ERCP pancreatitis in patients with self-expandable metal stent (SEMS) or plastic stent (PS).

2. New Mutations in APC andCatenin Gene in Wnt Signaling Pathway in Iranian Gastric Adenocarcinoma. *Gut 52 (Supple VI) 2003: A22.*
3. Immunohistochemical analysis of P53,Cyclin D1, c-Fos and N-Ras Genes Expression in hepatocellular carcinoma in Iran. *Gut 52 (Supple VI) 2003: A69.* S.
4. The expression of E-Cadherin in gastric cancer carcinomas: *A clinicopathological study. Gut 52 (Supple VI) 2003: A146.*
5. Correlation of Nuclear P53 Immunoreaction with the Histopathologic Features in Gastric Carcinoma. *Archives of Iranian Medicine 7(4): 279-283, 2004.*
6. Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. *World J Gastroenterology 2007 March 14; 13(10): 1528-1533.*
7. Clinicopathological Significance of E-cadherin, β-catenin and p53Expression in Gastric Adenocarinoma. *Journal of Research in Medical Sciences,2009.*
8. Biliary brush cytology in the assessment of biliary strictures at a tertiary center in Iran. *Asian Pac J Cancer Prev. 2011;12(10):2793-6.*
9. Data Mining and Application in Accounting and Auditing.Journal of Education and Vocational Research Vol. 2, No. 6, pp. 211-215, Dec 2011 (ISSN 2221-2590).
10. High frequency of microsatellite instability in sporadic colorectal cancer patients in Iran. *Genet Mol Res. 2011 Dec 14;10(4):3520-9. doi: 10.4238/2011.December.14.4.*
11. Clinical and histological indicators of proximal and distal gastric cancer in eight provinces of Iran. *Asian Pac J Cancer Prev. 2012;13(11):5677-9.*
12. Clinical characteristics of gastric cancer in different part of Iran: proximal vs. distal cancer. Asian Pac J Cancer Prev. 2012;13(11):5677-9.
13. Polymorphism in two short tandem repeat loci (R-R and S -Q) linked to tRNA genes in Entamoebadispar isolates. *GastroenterolHepatol Bed Bench. 2012 Autumn; 5(4): 202–208.*
14. The Effect of Board Composition on Conservatism: Empirical Evidence from Tehran Stock Exchange (TSE). Journal of Education and Vocational Research Vol. 3, No. 1, pp. 17-24, Jan 2012 (ISSN 2221-2590).
15. Primary Sclerosing Cholangitis associated with elevated immunoglobulin-G4. *Journal of DigestiveDiseases 2012.*
16. Correlation between the H. pylori density and urease activity in comparison to host's histopathological disorders. *HealthMED Journal.2012*
17. Allele-Specific Polymerase Chain Reaction for Detection of Main gyrA Allelic Variants in Helicobacter pylori Strains. *Arch Clin Infect Dis. 2013 October; 8(4): e19312.*
18. Clinical implications of BRAF mutation test in colorectal cancer. *GastroenterolHepatol Bed Bench. 2013 Winter;6(1):6-13.*
19. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer. *GastroenterolHepatol Bed Bench. 2013 Fall;6(4):178-82.*
20. The CpG island methylator phenotype (CIMP) in colorectal cancer. *GastroenterolHepatol Bed Bench. 2013 Summer;6(3):120-8.*
21. MUTYH the base excision repair gene family member associated with colorectal cancer polyposis. GastroenterolHepatol Bed Bench 2013;6(Suppl.1):S1-S10.
22. Metabonomics exposes metabolic biomarkers of Crohn's disease by HNMR. GastroenterolHepatol Bed Bench 2013;6(Suppl.1):S19-S22.
23. Different frequency of epidermal growth factor rs76189946 polymorphism genotype in an Iranian colorectal cancer. GastroenterolHepatol Bed Bench. 2013; 6(Suppl 1): S32–S38.

24. Adenomatous polyposis coli gene large deletions in Iranian patients with familial adenomatous polyposis. *Indian J Cancer. 2014 July-September;51(3):352-357. doi: 10.4103/0019-509X.146758.*
25. Smoking, proton Pump Inhibitors and Antibiotic Administration as Factors Affecting Direct Screening of Helicobacter Pylori Infection Among Patients With Dyspepsia. *Arch Clin Infect Dis. 2014 April; 9(2): e15774.*
26. Jejunojejunal Intussusception Caused by a Jejunal Villous Adenoma Polyp in an Adult. *Ann Colorectal Res. 2014 December; 2(4): e25420.*
27. Lack of Influence of the SMAD7 Gene rs2337107 Polymorphism on Risk of Colorectal Cancer in an Iranian Population. *Asian Pac J Cancer Prev. 2014;15(11):4437-41.*
28. Polymorphism of SMAD7 gene (rs2337104) and risk of colorectal cancer in an Iranian population: a case-control study. *GastroenterolHepatol Bed Bench. 2014 Fall;7(4):198-205.*
29. Potential treatment of inflammatory bowel disease: a review of helminths therapy. *GastroenterolHepatol Bed Bench. 2014 Winter;7(1):9-16.*
30. Association of miR-196a2 (rs11614913) polymorphism with colorectal cancer in Tehran population. *MEDICAL SCIENCES 2014, 23(4 and 1): 11-15.*
31. Evaluation of Polymorphisms rs762624 and rs3176336 of CDKN1A Gene and Risk of Colorectal Cancer. British Journal of Medicine and Medical Research 2014 4 (32), 5098.
32. Single Nucleotide Polymorphism (K589E) of the EXO1 Gene: Association with Colorectal Cancer Susceptibility and Clinicopathological Features. *GastroenterolHepatol Open Access 2014, 1(3): 00018.*
33. The prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/ COX2) rs5277 polymorphism does not influence risk of colorectal cancer in an Iranian population. *Asian Pac J Cancer Prev. 2014;15(8):3507-11.*
34. Novel Missense Mutation at Codon 2774 (C.8321 G>A) p.S2774N of APC Gene in a Denovo Case of Familial Adenomatous Polyposis. *Archives of Iranian Medicine, Volume 18, Number 7, July 2015.*
35. Effect of vitamin D3 supplementation on TNF-α serum level and disease activity index in Iranian IBD patients. *GastroenterolHepatol Bed Bench. 2015 Winter; 8(1): 49–55.*
36. Low level of microsatellite instability (MSL) correlates with poor clinical prognosis in Stage II colorectal cancer patients, *Received 30 December 2015; Accepted 19 May 2016.*
37. Comparison study on effect of different methods on DNA extraction of Methanobrevibactersmithii Biological Forum 7.2 (2015): 549-553.
38. Time trend analysis and demographic features of inflammatory bowel disease in Tehran. GastroenterolHepatol Bed Bench 2015;8(4):253-261.
39. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer. *Tumor Biology, 2015.*
40. Information Engineering and Workflow Design in a Clinical Decision Support System for Colorectal Cancer Screening in Iran. Asian Pacific Journal of Cancer Prevention, Vol 16, 2015.
41. Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomes. GastroenterolHepatol Bed Bench 2015;8(Suppl.1):S1-S5.
42. Evaluation of Insulin Like Growth Facror-1 Genetic Polymorphism with Gastric Cancer Susceptibility and Clinicopathological Features. Asian Pacific Journal of Cancer Prevention, Vol 16, 2015.

43. Lack of Association between Tumor Necrosis Factor Alpha (TNFα) Gene -1031C/T Polymorphisms and Susceptibility to Inflammatory Bowel Disease (IBD). *Arak University of Medical Sciences Journal. 2016; 19 (3) :71-79.*
44. An experimental model of colitis induced by dextran sulfate sodium from acute progresses to chronicity in C57BL/6: correlation between conditions of mice and the environment. GastroenterolHepatol Bed Bench. 2016 Winter; 9(1): 45–52.
45. Association between two single base polymorphisms of intercellular adhesion molecule 1 gene and inflammatory bowel disease. GastroenterolHepatol Bed Bench 2016;9(2):87-93.
46. Celiac disease. Arvand J Health Med Sci 2016;1(2):57-60.
47. Clinico-pathological patterns of colorectal cancer patients in Tehran, Iran. Arvand J Health Med Sci 2016;1(1):9-16.
48. Comparison of three methods for mitochondria isolation from the human liver cell line (HepG2). GastroenterolHepatol Bed Bench 2016;9(2):105-113.
49. Correlation between *JAK2V617F* mutation and inflammatory bowel disease in patients referring to Taleghani hospital, Tehran.Koomesh 2016 Vol.17 No.3 pp.Pe603-Pe612, En68 ref.45.
50. Designing Clinical and Genetic Guidelines of Colorectal Cancer Screening as an Effective Roadmap for Risk Managementic. Gastroenterology and Hepatology from bed to bench, Vol 9, (2016): Supplement
51. Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population. MicroRNA, Volume 5, Number 2, August 2016, pp. 152-156(5).
52. Lack of BRAFV600E mutation in stage I and II of colorectal cancer. GastroenterolHepatol Bed Bench 2016;9(2):94-99.
53. Low Level of Microsatellite Instability Correlates withPoor Clinical Prognosis in Stage II Colorectal Cancer Patients.Journal of Oncology Volume 2016, Article ID 2196703, 9 pages.
54. Pathological and Clinical Correlation between CeliacDisease and Helicobacter Pylori Infection; a Review ofControversial Reports. Middle East Journal of Digestive Diseases/ Vol.8/ No.2/ April 2016.
55. Relationship between ureB Sequence Diversity, Urease Activity and Genotypic Variations of Different Helicobacter pylori Strains in patients with gastric disorders. Polish Journal of Microbiology 2016,Vol.65,No2,153–159.
56. Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients. Gut Pathogens20179:1. DOI: 10.1186/s13099-016-0151-z.
57. Expression of CD86 Co-stimulatory gene in colon polyps.
58. Person centered prediction of survival in population based screening program by an intelligent clinical decision support system. Gastroenterol Hepatol Bed Bench v.10(1); Winter 2017PMC5346826
59. TGF-β1 polymorphisms-509 C> T and+ 915 G> C and risk of pancreatic cancer. Gastroenterology and Hepatology from bed to bench 10 (1), 14
60. Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A case report supporting the concept of tumoral heterogeneity. Cell J v.19(Suppl 1); Spring 2017 PMC5448326
61. Clinical Value of Human Leucocyte Antigen G (HLA-G) Expression in the Prognosis of Colorectal Cancer. International Journal of Cancer Management: April 2017, 10(4); e9346.Published Online: March 26, 2017

62. The necessity of gut microbiome characterization in diseases prevention and therapy. Gastroenterol Hepatol Bed Bench 2017;10(2):150-151
63. Relative Abundance of Streptococcus spp. and its Association with Disease Activity in Inflammatory Bowel Disease Patients Compared with Controls. Arch Clin Infect Dis. In Press (In Press):e57291.
64. Promoter hypermethylation of RAR-β tumor suppressor gene in gastric carcinoma: Association with histological type and clinical outcomes. Cancer Biomarkers, vol. 20, no. 1, pp. 7-15, 2017. DOI: 10.3233/CBM-160331
65. Investigation of a common gene expression signature in gastrointestinal cancers using systems biology approaches. Mol. BioSyst., 2017, 10.1039/C7MB00450H
66. Designing evidence based risk assessment system for cancer screening as an applicable approach for the estimating of treatment roadmap. BMJ Open 2017 7: doi: 10.1136/bmjopen-2016-015415.43
67. Polyp detection rate and pathological features in patients undergoing a comprehensive colonoscopy screening. World J Gastrointest Pathophysiol. 2017 Feb 15; 8(1): 3–10. Published online 2017 Feb 15. doi: 10.4291/wjgp.v8.i1.3
68. Is the study of gut microbiome necessary? Gastroenterology and Hepatology from bed to bench. 2017
69. The first study on opportunistic intestinal microsporidiosis in IBD patients receiving immunosuppressive medications in Iran. Epidemiology & Infection DOI: https://doi.org/10.1017/S0950268817000954 Published online: 15 May 2017
70. Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. BIOMEDICAL REPORTS 6: 698-702, 2017 DOI: 10.3892/br.2017.908
71. SUMO1 pseudogene 3 (SUMO1P3) expression in human gastric cancer and its clinical significance. world family medicine/middle east journal of family medicine volume 15 issue 5, july 2017
72. Germline mutation at codon 1309 of the adenomatous polyposis coli gene and exteracolonic manifestations in familial adenomatous polyposis. Tehran Univ Med J 2017, 75(4): 259-266
73. Comparative Evaluation of IL-16 mRNA level and rs1131445 polymorphism of IL-16 gene in Peripheral Blood Mononuclear Cells of patients with Inflammatory Bowel Diseases. South Asian Journal of Experimental Biology, Vol 6, No 6 (2016)
74. Distribution and phylogenetic analysis of Blastocystis sp. subtypes isolated from IBD patients and healthy individuals in Iran. Eur J Clin Microbiol Infect Dis DOI 10.1007/s10096-017-3065-x
75. Prevalence of Cytotoxin-associated genes of Helicobacter pylori among Iranian GERD patients. Gastroenterology and Hepatology from bed to bench 2017
76. One systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information. 2017/8/5. Gastroenterology and Hepatology from bed to bench
77. Gut microbiota, epigenetic modification and colorectal cancer. Iranian Journal of Microbiology 9 (2), 55-63 2017
78. Relative quantification of AXIN2 mRNA expression in different pathological types of colorectal polyps. Iranian Journal of Microbiology 9 (2), 55-63, 2017

79. Transmembrane TNF-[alpha] Density, but not Soluble TNF-[alpha] Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clinical and Translational Gastroenterology 8 (9), 2017
80. Detection of enterotoxigenic Bacteroides fragilis in patients with ulcerative colitis. Gut Pathogens 9 (1), 53, 2017
81. Syphacia obvelata: A New Hope to Induction of Intestinal Immunological Tolerance in C57BL/6 Mice. Korean J Parasitol. 2017 Aug; 55(4): 439–444.
82. IgG4 Associated Cholangiopathy: Diagnosis, Treatment, and Outcome. GOVARESH 2017. 22(3):139-148.
83. Network analysis of common genes related to esophageal, gastric, and colon cancers. Gastroenterology and Hepatology From Bed to Bench Vol 10, No 4 (2017): Autumn
84. Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews. Digestive Diseases and Sciences. December 2017, Volume 62, Issue 12, pp 3280–3286
85. Evaluating the expression level of co-stimulatory molecules CD 80 and CD 86 in different types of colon polyps. Current research in translational medicine.
86. Detailed analysis of total colectomy on health-related quality of life in adult patients with ulcerative colitis. Gastroenterology and Hepatology from bed to benchVol 10 (2017): Supplement 1 -Winter
87. Protein-protein interaction analysis of Alzheimers disease and NAFLD based on systems biology methods unhide common ancestor pathways. Gastroenterol Hepatol Bed Bench. 2018 Winter; 11(1): 27–33.
88. Genetic association between a single nucleotide polymorphism in Interleukin-16 (rs4072111) and susceptibility to chronic HCV infection in an Iranian population. Gastroenterol Hepatol Bed Bench. 2018 Winter; 11(1): 42–47.
89. Study the effects of mesenchymal stem cell conditioned medium injection in mouse model of acute colitis. International immunopharmacology 54, 86-94
90. Investigating the association between miR-608 rs4919510 and miR-149 rs2292832 with Colorectal Cancer in Iranian Population. MicroRNA (Shariqah, United Arab Emirates)
91. The application of gene expression profiling in predictions of occult lymph node metastasis in colorectal cancer patients. Biomedicines 2018, 6(1), 27; doi:10.3390/biomedicines6010027
92. Molecular and phylogenetic evidences of dispersion of human-infecting microsporidia to vegetable farms via irrigation with treated wastewater: One-year follow up. International journal of hygiene and environmental health 2018
93. Detection of B. fragilis group and diversity of bft enterotoxin and antibiotic resistance markers cepA, cfiA and nim among intestinal Bacteroides fragilis strains in patients with inflammatory bowel disease. Anaerobe. 2018 Apr;50:93-100. doi: 10.1016/j.anaerobe.2018.02.005. Epub 2018 Feb 14.
94. Alterations of the human gut brevibacter smithii as a biomarker for inflammatory bowel diseases. Microb Pathog. 2018 Apr;117:285-289. doi: 10.1016/j.micpath.2018.01.029. Epub 2018 Feb 22.
95. Detection of Parvovirus 4 in Iranian patients with HBV, HCV, HIV mono-infection, HIV and HCV co-infection. Gastroenterology and Hepatology From Bed to Bench Vol 11, No 2 (2018): Spring

96. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterology Journal 0(0) 1–9 DOI: 10.1177/2050640618774637
97. Study of Blastocystis frequency among IBD patients referred to a gastroenterology center. Infectious agents- Diseases- Surgery DOI: 10.22059/ijvm.2017.241887.1004845
98. Genetic diversity and functional analysis of oipA gene in association with other virulence factors among Helicobacter pylori isolates from Iranian patients with different gastric diseases. Infection, Genetics and Evolution 60, 26-34
99. Lack of Association between Interleukin 23R (IL-23R) rs10889677 Polymorphism and Inflammatory Bowel Disease Susceptibility In an Iranian Population. Reports of Biochemistry & Molecular Biology. Vol.7, No.1, Oct 2018
100. Diverse Profiles of Toll-Like Receptors 2, 4, 7, and 9 mRNA in Peripheral Blood and Biopsy Specimens of Patients with Celiac Disease. Journal of Immunology Research Volume 2018, Article ID 7587095, 8 pages https://doi.org/10.1155/2018/7587095
101. Transcultural Adaptation and Validation of Persian Version of Celiac Disease Questionnaire (CDQ); A Specific Questionnaire to Measure Quality of Life of Iranian Patients. Galen Medical Journal, 2018 DOI: http://dx.doi.org/10.22086/gmj.v0i0.1106
102. Impacts of Human Development Index and Climate Conditions on Prevalence of Blastocystis: a Systematic review and Meta-analysis. Acta Tropica Volume 185, September 2018, Pages 193-203
103. The immunomodulatory effects of adipose-derived mesenchymal stem cells and mesenchymal stem cells-conditioned medium in chronic colitis. Journal of Cellular Physiology, 2018
104. Quantitation of Colonic Cells as Severity Markers in Patients with Irritable Bowel Syndrome. Galen Medical Journal, 2018
105. An improved real-time qPCR technique for quantification of intestinal bacteria in human fecal samples. South Asian Journal of Experimental Biology, 2018
106. Contributions of HLA haplotypes, IL8 level and Toxoplasma gondii infection in defining celiac disease's phenotypes. BMC Gastroenterology2018**18**:66 https://doi.org/10.1186/s12876-018-0796-9
107. Small-scale risk assessment of transmission of parasites from wastewater treatment plant to downstream vegetable farms. Gastroenterology and Hepatology from bed to bench DOI: http://dx.doi.org/10.22037/ghfbb.v11i4.1419
108. A Rare Presentation of Simple Renal Cyst: Gastrointestinal Obstruction. Gastroenterology and Hepatology from bed to bench. Gastroenterology and Hepatology from bed to bench 11 (4), 1464-1464
109. The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. Microbial Pathogenesis Volume 124, November 2018, Pages 244-249
110. The Role of Angiogenesis in Colorectal Polyps and Cancer, a Review. Medical Laboratory Journal mljgoums. 2018; 12 (4) :1-6
111. Investigation of adherent-invasive E. coli in patients with Crohn's disease. Medical Journal of the Islamic Republic of Iran 32, 11
112. Hif-1 alpha gene expression is not a suitable biomarker for evaluating malignancy risk in colorectal polyps. WORLD CANCER RESEARCH JOURNAL 5 (3)

113. Can Giardia Infection Impair the Diagnostic Level of Fecal Calprotectin in Patients with Inflammatory Bowel Disease? A Case Report IRANIAN JOURNAL OF PARASITOLOGY 13 (3), 505-509
114. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features Journal of cellular physiology
115. The relationship between 174 G/C and-572 G/C of IL-6 gene polymorphisms and susceptibility of celiac disease in the Iranian population. Prz Gastroenterol. 2018; 13(4): 293–298.
116. miR-30a promoter variation contributes to the increased risk of colorectal cancer in an Iranian population. J Cell Biochem. 2018 Nov 1. doi: 10.1002/jcb.28047.
117. Seroprevalence of Toxoplasma gondii, HBV and HCV infections. Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 November;177(11):624-9
118. Applying simple linear combination, multiple logistic and factor analysis methods for candidate fecal bacteria as novel biomarkers for early detection of adenomatous polyps and colon cancer. J Microbiol Methods. 2018 Dec;155:82-88. doi: 10.1016/j.mimet.2018.11.007. Epub 2018 Nov 12.
119. SRC and TP53 play critical role in low-grade dysplasia colorectal mucosa transformation into cancer. Gastroenterology and Hepatology from Bed to Bench, 1534-1534
120. Apoptosis markers of circulating leukocytes are associated with the clinical course of inflammatory bowel disease. Gastroenterology and Hepatology from Bed to Bench, 1453-1453
121. Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases. Gastroenterol Hepatol Bed Bench 2018;11(Suppl. 1):S124-S128).
122. Interleukin 12B mRNA level and rs3212227 genotyping in peripheral blood mononuclear cells of inflammatory bowel disease patients. Turkish journal of medical sciences 48 (6), 1147-1152
123. MSI-L/EMAST is a predictive biomarker for metastasis in colorectal cancer patients. J Cell Physiol. 2018 Dec 13. doi: 10.1002/jcp.27983.
124. HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy. J Cell Physiol. 2018 Dec 13. doi: 10.1002/jcp.27984
125. Association between Interleukin-21 and Interleukin-21 receptor gene polymorphisms with susceptibility to chronic hepatitis B virus infection and HBV spontaneous clearance in Iranian population. Microb Pathog. 2019 Jan 9. pii: S0882-4010(18)30890-8. doi: 10.1016/j.micpath.2019.01.008
126. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability. J Gastrointest Cancer. 2019 Jan 12. doi: 10.1007/s12029-019-00201-4
127. High prevalence of antibiotic resistance in Helicobacter pylori isolates from Iran: importance of functional and mutational analysis of resistance genes and virulence genotyping. BioRxiv, 2019
128. Conditioned Medium from Cultured Colorectal Cancer Cells Affects Peripheral Blood Mononuclear Cells Inflammatory Phenotype in Vitro. Iranian Journal of Medical Sciences, 2019
129. A gene variation of interferon gamma receptor-I promoter (rs1327474A> G) and chronic hepatitis C virus infection. Gastroenterology and Hepatology from Bed to Bench, 2019

130. A detailed image of rutin underlying intracellular signaling pathways in human SW480 colorectal cancer cells based on miRNAs-lncRNAs-mRNAs-TFs interactions. Journal of cellular physiology, 2019
131. Investigation of health benefits of cocoa in human colorectal cancer cell line, HT-29 through interactome analysis Gastroenterology and Hepatology from Bed to Bench, 2019
132. Prevalence of gluten-related disorders in Asia-Pacific region: a systematic review. Journal of Gastrointestinal & Liver Diseases, 2019
133. Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening. Journal of Crohn's and Colitis, 2019
134. The gut microflora assay in patients with colorectal cancer: in feces or tissue samples?. Iranian Journal of Microbiology, 2019
135. Investigating the diagnostic performance of HOTTIP, PVT1, and UCA1 long noncoding RNAs as a predictive panel for the screening of colorectal cancer patients with lymph node metastasis. Journal of cellular biochemistry, 2019
136. Bioburden and transmission of pathogenic bacteria through elevator channel during endoscopic retrograde cholangiopancreatography: application of multiple-locus variable-number tandem-repeat analysis for characterization of clonal strains. Expert review of medical devices, 2019
137. V617F-independent upregulation of JAK2 gene expression in patients with inflammatory bowel disease. Journal of cellular biochemistry, 2019
138. Prevalence and characterization of Clostridium perfringens toxinotypes among patients with antibiotic-associated diarrhea in Iran. Scientific Reports, 2019

Accepted posters:

1. Mutational analysis of APC gene, immunoreactivity of p53, and E-Cadherin protein in gastric adenocarcinoma. *51 Th Annual meeting of The American Society of Human Genetics. San Diego, CA, October 2001.*
2. Identification and Analysis of Mutations in the Gastric Cancer in Iran. *World Congress of Gastroenterology February 2002. Bangkok,Thailand.*
3. New Mutations in APC and B-Catenin Gene in Wnt Signaling Pathway in Iranian Gastric Adenocarcinoma. Oral Presentation, *Travel Grant Awarded for the excellent quality of the Abstract.11th UEGW 2003. Madrid, Spain.* H. AsadzadehAghdaee,
4. Molecular detection ofgermline mutations of the hMLH1 & hMSH2 Genes Among Iranian HNPCC patients. 11th UEGW 2003. Madrid, Spain.
5. Immunohistochemical analysis of P53, Cyclin D1, c-Fos and N-Ras Genes Expression in hepatocellular carcinoma in Iran.*11th UEGW 2003. Madrid, Spain.*
6. The expression of E-Cadherin in gastric cancer carcinomas: A clinicopathological study. *11th UEGW 2003. Madrid, Spain.*
7. Microsatellite instability as a molecular screening test for detection of hereditary non-polyposis colorectal cancer in Iranian population. *Digestive Disease Week 2003. Orlando, Florida, USA.*
8. B. Fragilis as Dominant Species of BacteroidesFragilis Group in Patients with IBD B. fragilis as dominant species of Bacteroidesfragilis group in patients with IBD. *Iranian and International Congress of Micorbiology, Ardabil, Iran, jun. 2012.*

9. PTU-199 Proinflammatory Cytokine (Il-8) in Microscopic Enteritis. *Gut 2013;62:A130 doi:10.1136/gutjnl-2013-304907.289*
10. Evaluation of polymorphisms rs762624 and rs3176336 of CDKN1A gene and risk of colorectal cancer. *British Journal of Medicine and Medical Research 01/2014; 4(32):5098-5106. DOI: 10.9734/BJMMR/2014/8762*
11. Comparison study on effect of different methods on DNA extraction Of Methanobrevibactersmithii. *Biological Forum–An International Journal 7(2): 549-553(2015)*
12. Correlation between JAK2V617F mutation and inflammatory bowel disease in patients referring to Taleghani hospital, Tehran. 2016 Vol.17 No.3 pp.Pe603-Pe612, En68 ref.45
13. VEGF gene +936C/T polymorphism decreases the risk of colorectal cancer
14. Relative quantification of AXIN2 mRNA expression in different pathological types of colorectal polyps. Tehran University Medical Journal TUMS Publications, 2017
15. Evaluation of expression of CTGF and MMP-1 in colon cancer patients. Advisor. 2019

Gene submission

1. Clostridium perfringens strain RIGLD-1 accessory gene regulator D (agrD) gene, complete cds
135 bp linear DNA MH377337.1 GI:1569272548
2. Clostridium perfringens strain RIGLD-2 accessory gene regulator D (agrD) gene, complete cds
135 bp linear DNA MH377338.1 GI:1569272550
3. Clostridium perfringens strain RIGLD-4 accessory gene regulator D (agrD) gene, complete cds
135 bp linear DNA MH377339.1 GI:1569272552
4. Clostridium perfringens strain RIGLD-5 accessory gene regulator D (agrD) gene, complete cds
135 bp linear DNA MH377340.1 GI:1569272554
5. Clostridium perfringens strain RIGLD-6 accessory gene regulator D (agrD) gene, complete cds
135 bp linear DNA MH377341.1 GI:1569272556
6. Clostridium perfringens strain RIGLD-9 accessory gene regulator D (agrD) gene, complete cds
135 bp linear DNA MH377342.1 GI:1569272558
7. Clostridium perfringens strain RIGLD-10 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377343.1 GI:1569272560
8. Clostridium perfringens strain RIGLD-11 accessory gene regulator D (agrD) gene, complete cds 135 bp linear DNA MH377344.1 GI:1569272562
9. Clostridium perfringens strain RIGLD-15 accessory gene regulator D (agrD) gene, complete cds 135 bp linear DNA MH377345.1 GI:1569272564
10. Clostridium perfringens strain RIGLD-24 accessory gene regulator D (agrD) gene, complete cds 135 bp linear DNA MH377346.1 GI:1569272566
11. Clostridium perfringens strain RIGLD-25 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377347.1 GI:1569272568

12. Clostridium perfringens strain RIGLD-26 accessory gene regulator D (agrD) gene, complete cds 135 bp linear DNA MH377348.1 GI:1569272570
13. Clostridium perfringens strain RIGLD-27 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377349.1 GI:1569272572
14. Clostridium perfringens strain RIGLD-29 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377350.1 GI:1569272574
15. Clostridium perfringens strain RIGLD-32 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377351.1 GI:1569272576
16. Clostridium perfringens strain RIGLD-34 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377352.1 GI:1569272578
17. Clostridium perfringens strain RIGLD-35 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377353.1 GI:1569272580
18. Clostridium perfringens strain RIGLD-36 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377354.1 GI:1569272582
19. Clostridium perfringens strain RIGLD-37 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377355.1 GI:1569272584
20. Clostridium perfringens strain RIGLD-41 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377356.1 GI:1569272586
21. Clostridium perfringens strain RIGLD-42 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377357.1 GI:1569272588
22. Clostridium perfringens strain RIGLD-43 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377358.1 GI:1569272590
23. Clostridium perfringens strain RIGLD-44 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377359.1 GI:1569272592
24. Clostridium perfringens strain RIGLD-45 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377360.1 GI:1569272594
25. Clostridium perfringens strain RIGLD-46 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377361.1 GI:1569272596
26. Clostridium perfringens strain RIGLD-47 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377362.1 GI:1569272598
27. Clostridium perfringens strain RIGLD-49 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377363.1 GI:1569272600
28. Clostridium perfringens strain RIGLD-50 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377364.1 GI:1569272602
29. Clostridium perfringens strain RIGLD-51 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377365.1 GI:1569272604
30. Clostridium perfringens strain RIGLD-53 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377366.1 GI:1569272606
31. Clostridium perfringens strain RIGLD-54 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377367.1 GI:1569272608
32. Clostridium perfringens strain RIGLD-55 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377368.1 GI:1569272610
33. Clostridium perfringens strain RIGLD-56 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377369.1 GI:1569272612
34. Clostridium perfringens strain RIGLD-58 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377370.1 GI:1569272614

35. Clostridium perfringens strain RIGLD-59 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377371.1 GI:1569272616
36. Clostridium perfringens strain RIGLD-60 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377372.1 GI:1569272618
37. Clostridium perfringens strain RIGLD-61 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377373.1 GI:1569272620
38. Clostridium perfringens strain RIGLD-62 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377374.1 GI:1569272622
39. Clostridium perfringens strain RIGLD-63 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377375.1 GI:1569272624
40. Clostridium perfringens strain RIGLD-64 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377376.1 GI:1569272626
41. Clostridium perfringens strain RIGLD-65 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377377.1 GI:1569272628
42. Clostridium perfringens strain RIGLD-66 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377378.1 GI:1569272630
43. Clostridium perfringens strain RIGLD-67 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377379.1 GI:1569272632
44. Clostridium perfringens strain RIGLD-68 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377380.1 GI:1569272634
45. Clostridium perfringens strain RIGLD-69 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377381.1 GI:1569272636
46. Clostridium perfringens strain RIGLD-70 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377382.1 GI:1569272638
47. Clostridium perfringens strain RIGLD-71 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377383.1 GI:1569272640
48. Clostridium perfringens strain RIGLD-72 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377384.1 GI:1569272642
49. Clostridium perfringens strain RIGLD-73 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377385.1 GI:1569272644
50. Clostridium perfringens strain RIGLD-74 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377386.1 GI:1569272646
51. Clostridium perfringens strain RIGLD-75 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377387.1 GI:1569272648
52. Clostridium perfringens strain RIGLD-79 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377388.1 GI:1569272650
53. Clostridium perfringens strain RIGLD-80 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377389.1 GI:1569272652
54. Clostridium perfringens strain RIGLD-81 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377390.1 GI:1569272654
55. Clostridium perfringens strain RIGLD-82 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377391.1 GI:1569272656
56. Clostridium perfringens strain RIGLD-83 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377392.1 GI:1569272658
57. Clostridium perfringens strain RIGLD-85 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377393.1 GI:1569272660

58. Clostridium perfringens strain RIGLD-88 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377394.1 GI:1569272662
59. Clostridium perfringens strain RIGLD-89 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377395.1 GI:1569272664
60. Clostridium perfringens strain RIGLD-90 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377396.1 GI:1569272666
61. Clostridium perfringens strain RIGLD-91 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377397.1 GI:1569272668
62. Clostridium perfringens strain RIGLD-93 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377398.1 GI:1569272670
63. Clostridium perfringens strain RIGLD-94 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377399.1 GI:1569272672
64. Clostridium perfringens strain RIGLD-95 accessory gene regulator D (agrD) gene, complete cds135 bp linear DNA MH377400.1 GI:1569272674
65. Clostridium perfringens strain RIGLD-33 16S ribosomal RNA gene, partial sequence
230 bp linear DNA MH997495.1 GI:1483728635
66. Blastocystis sp. isolate B1 small subunit ribosomal RNA gene, partial sequence 578 bp linear DNA MH915564.1 GI:1476588008
67. Blastocystis sp. isolate B2 small subunit ribosomal RNA gene, partial sequence 558 bp linear DNA MH915565.1 GI:1476588009
68. Blastocystis sp. isolate B3 small subunit ribosomal RNA gene, partial sequence556 bp linear DNA MH915566.1 GI:1476588010
69. Blastocystis sp. isolate B4 small subunit ribosomal RNA gene, partial sequence538 bp linear DNA MH915567.1 GI:1476588011
70. Encephalitozoon hellem isolate 1 small subunit ribosomal RNA gene, partial sequence491 bp linear DNA MG584868.1 GI:1280931437
71. Encephalitozoon hellem isolate 2 small subunit ribosomal RNA gene, partial sequence467 bp linear DNA MG584869.1 GI:1280931438
72. Enterocytozoon bieneusi isolate 1 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence373 bp linear DNA MG491314.1 GI:1276727567
73. Enterocytozoon bieneusi isolate 2 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence346 bp linear DNA MG491315.1 GI:1276727568
74. Enterocytozoon bieneusi isolate 3 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence365 bp linear DNA MG491316.1 GI:1276727569
75. Enterocytozoon bieneusi isolate 4 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence373 bp linear DNA MG491317.1 GI:1276727570
76. Enterocytozoon bieneusi isolate 5 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence365 bp linear DNA MG491318.1 GI:1276727571
77. Enterocytozoon bieneusi isolate 6 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence365 bp linear DNA MG491319.1 GI:1276727572

78. Enterocytozoon bieneusi isolate 7 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence377 bp linear DNA MG491320.1 GI:1276727573
79. Enterocytozoon bieneusi isolate 8 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence375 bp linear DNA MG491321.1 GI:1276727574
80. Enterocytozoon bieneusi isolate 9 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence365 bp linear DNA MG491322.1 GI:1276727575
81. Enterocytozoon bieneusi isolate 10 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence365 bp linear DNA MG491323.1 GI:1276727576
82. Enterocytozoon bieneusi isolate 11 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence365 bp linear DNA MG491324.1 GI:1276727577
83. Enterocytozoon bieneusi isolate 12 small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer, complete sequence; and large subunit ribosomal RNA gene, partial sequence365 bp linear DNA MG491325.1 GI:1276727578
84. Blastocystis hominis isolate BH2 18S ribosomal RNA gene, partial sequence521 bp linear DNA KX755866.1 GI:1214268995
85. Blastocystis hominis isolate BH3 18S ribosomal RNA gene, partial sequence511 bp linear DNA KX755867.1 GI:1214268996
86. Blastocystis hominis isolate BH4 18S ribosomal RNA gene, partial sequence490 bp linear DNA KX755868.1 GI:1214268997
87. Blastocystis hominis isolate BH5 18S ribosomal RNA gene, partial sequence355 bp linear DNA KX755869.1 GI:1214268998
88. Blastocystis hominis isolate BH6 18S ribosomal RNA gene, partial sequence438 bp linear DNA KX755870.1 GI:1214268999
89. Blastocystis hominis isolate BH7 18S ribosomal RNA gene, partial sequence515 bp linear DNA KX755871.1 GI:1214269000
90. Blastocystis hominis isolate BH8 18S ribosomal RNA gene, partial sequence502 bp linear DNA KX755872.1 GI:1214269001
91. Blastocystis hominis isolate BH2 18S ribosomal RNA gene, partial sequence494 bp linear DNA KX755873.1 GI:1214269002
92. Helicobacter pylori strain RIGLD HC164 IceA2 (iceA2) gene, complete cds662 bp linear DNA
KC153039.1 GI:440922392
93. Helicobacter pylori strain RIGLD OC159 OipA gene, partial cds747 bp linear DNA KC153040.1 GI:440922394
94. Homo sapiens interleukin 21 receptor (IL21R), transcript variant 2, mRNA4,837 bp linear mRNA NM_181078.3 GI:1519245734
95. Homo sapiens interleukin 21 receptor (IL21R), transcript variant 3, mRNA5,006 bp linear mRNA NM_181079.4 GI:302034747
96. Homo sapiens interleukin 21 receptor (IL21R), transcript variant 1, mRNA4,512 bp linear mRNA NM_021798.3 GI:301897868

Thesis

1. Correlation between the H. pylori density and urease activity in comparison to host's histopathological disorders. For obtaining Gastroenterology & Hepatology Sub-Specialty Diploma.
2. Molecular Detection of Germline Mutations of the hMLH1 &hMSH2 Genes among Iranian HNPCC (For obtaining Internal Medicine Specialty Diploma) Mentor: Proff. M. R. Zali, M. D., M. R. Abbaszadeghan, PhD Shaheed Beheshti University of Medical Sciences (SBUMS), 2000-2003. +98-21-2241-8871.
3. HLA Typing in family of HTLV-1 positive patient. (For obtaining Medical Diploma)Mentor: Dr. R. Farid and Dr. B. NikBin Mashhad University of Medical Sciences, 1994-1996+98511-761-1580.
4. Detection and Analysis of genetic mutations (APC, B- Catenine, E-Cadherin & P53) in Gastric Adenocarcinoma. Research Manager
5. Prevalence Determination of Familial Gastric Cancer in Iran in 2001-2003. Main Investigator.
6. MSI analysis in colorectal and endometrial cancers. Main Investigator.
7. Study of incidence of genetic & epigenetic changes in P14, P16 & K-ras genes in Colorectal cancer patients. Main Investigator.
8. Cancer risk assessment in family of esophageal cancer patients by new genetic biomarkers and balloon Cytology. Main Investigator.
9. Evaluation of colorectal neoplasm in patients with coronary heart disease. Main Investigator
10. Investigation of immunogenic effects of Syphacia obvelata in treatment of experimental DSS-colitis mouse model. Supervisor. 1396
11. Long non-coding RNA expression consisting AA 174084, UC0011sz, FER1L4, SUMO1P3 and ANRIL in gastric cancer patients and its clinical association. Advisor. 2017
12. Investigation of H. pylori cagPAI genotype and its association with expression profile of genes related to gastric cancer. Advisor. 2015
13. Association of miR-196a2 (rs11614913) polymorphism with colorectal cancer population Iran. Advisor. 2014
14. Study of Gut Microbiota and Its Association with Expression and Methylation of Important TLR Genes in Normal People and CRC Patients. Advisor. 2018
15. Analysis of expression of miRNA29 and its downstream gene TET2 in tumor samples and normal tissue of colon cancer in Iranian population. Advisor
16. Study of epigenetic changes of miR26 and TDG gene in the initial defects of the tumor (polyp), advanced tumor tissue of colon and normal tissue of the surrounding area. Advisor
17. Investigating the mechanism of epigenetic interference of non-coding miR-494 and miR-200 RNAs involved in TET1 molecular variations in the inferior colon cancer, tumor cells, HT-29 cell line, and 5-hydroxymethyl-cytosine in these tissues. Advisor
18. Investigation of the relationship between the recurrence of four nucleotide sequences with angiogenesis-associated genes in poor prognosis in patients with colon cancer. Advisor

19. Examine the expression of CTGF and MMP-1 genes in colon cancer patients. Advisor
20. The analysis of epigenetic changes in the expression of the non-coding RNA network of P53 and the total amount of 5-hydroxymethylcytosine in the primary colon cancer tissue and cell lines treated with cold atmospheric gas
21. Evaluation of BAX and BCL2 expression in IBD patients in remission and flare-up phase. Advisor
22. Evaluation of TNF-α expression in paraffin tissue of the intestine compared to control subjects using immunohistochemistry method. Advisor
23. Comparison of calprotectin gene expression in peripheral blood leukocytes with and without IBD. Advisor
24. Comparison of iNOS gene expression in peripheral blood leukocytes in patients with and without IBD. Supervisor
25. Investigating the Role of CagL Helicobacter Pylori Protein on Bacillus subtilis spores in the expression of genes associated with autophagy signaling pathways in AGS cell line. Advisor
26. Study of protease activity of Blactocystis sp, subtypes isolated from symptomatic and asymptomatic patients and its effects on inflammatory biomarkers on cell culture (HT29). Advisor. 2016
27. The Investigation of the Relationship Between JAK2 Gene and Inflammatory Disease (IBD) in Iranian Patients Referring to Tehran Taleghani Hospital Between 2011 and 2014. Advisor

PROFESSIONAL POSITIONS AND APPOINTMENTS

- 1996-1997 The senior family physician in an out-patient clinic.
- 2001-2002 Counselor of "Gastrointestinal Cancer Genetic Counseling Clinic" In RCGLD
- 2002-2005 Manager & Counselor of "Cancer Genetic Counseling Clinic" In a Private Office, Mashhad, Iran.
- 2002-2006 Working as an Internal Medicine Consultant in EbneSina Hospital
- 2004 Working as an Internist in Mousa-ben-Jafar Charity Hospital Mashhad, Iran.
- 2004-2005 Working as an internist in 22 Bahman general hospital affiliated With Azad University, Mashhad, Iran.
- 2006-2008 Head of Checkup clinic, Razavi hospital. Working as an Internal medicine consultant and Gastrointestinal endoscopist in Razavi hospital, Mashhad, Iran.
- 2007-2008 Head of Internal medicine department, Razavi hospital Head of endoscopy ward, Razavi hospital.
- 2008-2009 Working as an assistant professor in Islamic Azad university-Mashhad branch.
- 2011-Up to now Head of Basic Science and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 2011-Up to now Working as an assistant professor in Taleghani hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 2015 up to now: Vice Chancellor in Administration and Resources development Affairs in Research Institute for Gastroenterology & Liver Diseases, SBMU, Tehran, Iran.

TEACHING ACTIVITIES–HOSPITAL OR OFFICE-BASED

- Director of seventh National Conference of Iranian Students of Medical Sciences in "Allergy & Clinical Immunology", November 1993
- Chief resident of Internal Medicine Wards in Taleghani Hospital, Shaheed Beheshti University of Medical Sciences (SBUMS), Tehran, Iran.
- Executive manager of gastrointestinal lumen cancers congress. May 2008. Razavi Hospital, Mashhad, Iran.
- Scientific chairman of the first International Inflammatory Bowell Disease Congress, May 2013, Razavi Hospital, Mashhad, Iran.
- Scientific chairman of the first International Endosonography congress, May 2015, Razavi Hospital, Mashhad, Iran.
- Scientific chairman of the second International Endosonography congress, Sep 2017, RIGLD, SBMU, Tehran, Iran.

HOSPITAL/UNIVERSITY COMMITTEE APPOINTMENTS

- 1992-1994 Manager of Medical Students Research Center. MUMS, Mashhad, Iran
- 1997-1999 Working as a molecular biology technician in Genetic Dept. of Bu-ali Research Institute, MUMS, Mashhad, Iran.
- 1999-2002The fundamentals of research methodology and biostatics in Research Center for Gastroenterology and Liver Diseases (RCGLD); SBUMS, Tehran, Iran.
- March 2001 Molecular Biology Workshop; Genetic Research Center of Rehabilitation and Welfare University; Tehran, Iran.
- 2001-2002 Manager & Counselor of "Gastrointestinal Cancer Genetic Counseling Clinic" in RCGLD.
- 2002-2009 Working part time as a Clinical research methodologist & Cancer genetic counselor in Human Genetic Dept of Bu-ali Research Institute, MUMS, Mashhad, Iran.

PROFESSIONAL AND SOCIETY MEMBERSHIPS

- Member of the ethics committee of Shahid Beheshti Medical University. Tehran, Iran
- Manager of national project of CRC screening
- Department of Development and Support
- Protomics research center- Shahid Beheshti university of Medical Sciences
- Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases ,Shahid Beheshti University of Medical Sciences, Tehran, Iran

EDITORIAL ACTIVITIES

- Reviewer for Gastrointestinal and Hepatology from Bed to Bench Journal

LECTURES/PRESENTATIONS GIVEN AT LOCAL, CHAPTER, NATIONAL, INTERNATIONAL MEETINGS

Lecture presentations:

1. The fifth Congress of bile ducts and pancreas diseases 2011/09/28
2. The sixth Congress of bile ducts and pancreas diseases 2012/10/03
3. ERCP and Billiary Stent workshop 2012/10/03
4. International Congress on Coronary Artery Disease 2013/05/01
5. News in Colorectal Cancer 2013/05/01
6. The Seventh Congress of bile ducts and pancreas diseases 2013/10/02
7. Iranian Congress of Gastroenterology and Hepatology 2013/11/27
8. The First Congress of inflammatory bowel disease and gluten-related disorders

2014/05/28

9. Cholangioscopy in patients with primary sclerosing cholangitis Workshop 2014/05/29
10. The eighth Congress of bile ducts and pancreas diseases 2014/10/08
11. Congress of digestive endosonography 2015/10/07
12. The eighth Annual Congress of Coloproctology and incontinence 2014/11/12
13. The two-day seminar family doctor 2016/01/07
14. Challenges therapy and active surveillance in the treatment of gastrointestinal and liver diseases 2016/01/26
15. Hepatocellularcarcinoma 2016/01/28
16. Challenges therapy and active surveillance in the treatment of gastrointestinal and liver diseases 2016/02/02
17. Laboratory and Clinical Congress 2016/02/06
18. Inflammatory Bowel Diseases 2016/04/28
19. Congress of digestive emergency 2016/05/25
20. An Introduction with common Digestive and Liver Disorders 2016/06/07
21. Periodic scientific conference digestive diseases 2016/08/22
22. Gluten-related disorders 2016/09/01
23. Periodic scientific conference digestive diseases 2016/09/05
24. Periodic scientific conference digestive diseases 2016/09/19
25. International Congress of the pancreas and bile ducts 2016/09/26
26. Performing of Cholangioscopy 2016/09/27
27. Periodic scientific conference digestive diseases 2016/10/03
28. The role of herbal medicines in the treatment of gastrointestinal and internal diseases 2016/11/20
29. Third International Congress on Gastrointestinal Cancer 2016/11/23
30. Irritable Bowel Syndrome 2016/12/08
31. Periodic scientific conference digestive diseases 2016/12/26
32. Hepatocellularcarcinoma 2016/12/29
33. Periodic scientific conference digestive diseases 2017/01/09
34. Digestive pathology 2017/04/20
35. Digestive pathology 2017/05/11
36. Digestive pathology 2017/06/15
37. Common Digestive Diseases 2017/07/04
38. Digestive pathology 2017/08/10
39. Second International Endosonography Congress 2017.09.13
40. Digestive pathology 2017.10.12
41. Gastrointestinal Diseases (3) 2017.11.21
42. Gastrointestinal Diseases (4) 2017.11.21
43. Congress of Iranian Gastroenterology and Diseases 2017.10.23
44. Digestive pathology 2017.12.14
45. Digestive pathology 2018.01.11
46. Digestive pathology 2018.02.08
47. Challenges of inflammatory bowel disease 2019.02.07
48. Joint Digestive and Oncology Conference 2019.02.14

Participated Congress:

1. The fifth Congress of bile ducts and pancreas diseases 2011/09/28

2. International Congress of News in Cardiovascular Disease 2011/10/05
3. News surgical colon and rectum 2012/09/06
4. The sixth Congress of bile ducts and pancreas diseases 2012/10/03
5. Twelfth Gastroenterology and Hepatology Congress 2012/11/28
6. The Seventh Congress of bile ducts and pancreas diseases 2013/10/02
7. Proctology 2013/10/17
8. Iranian Congress of Gastroenterology and Hepatology 2013/11/27
9. The First Congress of inflammatory bowel disease and gluten-related disorders 2014/05/28
10. The eighth Congress of bile ducts and pancreas diseases 2014/10/08
11. Mental health 2014/12/03
12. Scientific conference corporate groups Gastroenterology and Surgery 2015/09/21
13. Scientific conference corporate groups Gastroenterology and Surgery 2015/10/05
14. Congress of digestive endosonography 2015/10/07
15. The one-day conference on research ethics 2015/11/11
16. Cell therapy in autoimmune and inflammatory diseases 2015/12/17
17. Gastroparesis 2016/01/07
18. Challenges therapy and active surveillance in the treatment of gastrointestinal and liver diseases 2016/01/26
19. Hepatocellularcarcinoma 2016/01/28
20. Challenges therapy and active surveillance in the treatment of gastrointestinal and liver diseases 2016/02/02
21. Laboratory and Clinical Congress 2016/02/06
22. Celiac disease symposium 2016/02/18
23. Dealing with the problems of inflammatory bowel disease 2016/02/28
24. Scientific conference corporate groups Gastroenterology and Surgery 2016/03/07
25. Liver disorders and pregnancy symposium 2016/03/10
26. Inflammatory Bowel Disease 2016/04/28
27. An overview of common gastrointestinal diseases 2016/05/04
28. An overview of common gastrointestinal diseases 2016/05/11
29. Congress of digestive emergency 2016/05/25
30. An introduction with common gastrointestinal and liver diseases 2016/06/07
31. Periodic scientific conference digestive diseases 2016/06/13
32. An overview of common gastrointestinal diseases 2016/06/29
33. Elastography Congress 2016/07/10
34. Periodic scientific conference digestive diseases 2016/07/25
35. Periodic scientific conference digestive diseases 2016/08/08
36. Periodic scientific conference digestive diseases 2016/08/22
37. Gluten-related disorders 2016/09/01
38. Periodic scientific conference digestive diseases 2016/09/05
39. Periodic scientific conference digestive diseases 2016/09/19
40. Performing of Cholangioscopy 2016/09/27
41. International Congress of bile ducts and pancreas diseases 2016/09/28
42. Periodic scientific conference digestive diseases 2016/10/03
43. Periodic scientific conference digestive diseases 2016/10/17
44. Periodic scientific conference digestive diseases 2016/10/31

45. Iranian Sixteenth Congress of Gastroenterology and Hepatology 2016/11/09
46. Periodic scientific conference digestive diseases 2016/11/14
47. The third International Congress on Gastrointestinal Cancer 2016/11/23
48. Periodic scientific conference digestive diseases 2016/12/12
49. Periodic scientific conference digestive diseases 2016/12/26
50. Hepatocellularcarcinoma 2016/12/29
51. Periodic scientific conference digestive diseases 2017/01/09
52. Digestive pathology 2017/04/20
53. Digestive pathology 2017/05/11
54. Digestive pathology 2017/06/15
55. Common Digestive Diseases 2017/07/04
56. Second International Endosonography Congress 2017.09.13
57. Gastrointestinal Diseases (4) 2017.11.21
58. Congress of Iranian Gastroenterology and Diseases 2017.10.23
59. Digestive pathology 2017.12.14
60. Digestive pathology 2018.01.11
61. Digestive pathology 2018.02.08
62. The role of herbal medicines in liver and digestive diseases 2018.10.4
63. Challenges of inflammatory bowel disease 2019.02.07

REFERENCES

1. M.R. zali, M.D., FACG, FAGA Professor of Gastroenterology President- Research Center for Gastroenterology & Liver Disease (RCGLD) SUMS, Tehran, Iran. E-mail: zali@rcgld.org. Home page: www.rcgld.org. Phone: +98-21-2418871
2. R. Farid, M.D., FCCP, Professor of Medical Allergy & Immunology Director, Dept. of Clinical Immunology MUMS, Mashhad, Iran. E-mail: rfaridh@yahoo.com. Phone: +98-511-8428014
3. M.R. Abbaszadegan, MT (ASCP), Ph.D., ABMG Assistant Professor Director, Division of Human Genetics Head, Bu-Ali Research Institute MUMS, Mashhad, Iran. E-mail: mabbaszadegan@hotmail.com. Phone: +98-511-762-7601
4. A. H. Alizadeh, M.D. Professor of Gastroenterology, Dept. of Gastroenterology,SUMS, Tehran, Iran.
   E-mail: hmaliver@yahoo.com. Phone: +98-912-821-9855

Dated: 2019-06-20